MilliporeSigma
  • Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression.

Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression.

Nature communications (2022-12-24)
Jaskaren Kohli, Chen Ge, Eleni Fitsiou, Miriam Doepner, Simone M Brandenburg, William J Faller, Todd W Ridky, Marco Demaria
ABSTRACT

Human melanocytic nevi (moles) result from a brief period of clonal expansion of melanocytes. As a cellular defensive mechanism against oncogene-induced hyperplasia, nevus-resident melanocytes enter a senescent state of stable cell cycle arrest. Senescent melanocytes can persist for months in mice and years in humans with a risk to escape the senescent state and progress to melanoma. The mechanisms providing prolonged survival of senescent melanocytes remain poorly understood. Here, we show that senescent melanocytes in culture and in nevi express high level of the anti-apoptotic BCL-2 family member BCL-W but remain insensitive to the pan-BCL-2 inhibitor ABT-263. We demonstrate that resistance to ABT-263 is driven by mTOR-mediated enhanced translation of another anti-apoptotic member, MCL-1. Strikingly, the combination of ABT-263 and MCL-1 inhibitors results in synthetic lethality to senescent melanocytes, and its topical application sufficient to eliminate nevi in male mice. These data highlight the important role of redundant anti-apoptotic mechanisms for the survival advantage of senescent melanocytes, and the proof-of-concept for a non-invasive combination therapy for nevi removal.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-BRAF (V600E) antibody, Rabbit monoclonal, recombinant, expressed in HEK 293 cells, clone RM8, purified immunoglobulin
Sigma-Aldrich
Monoclonal Anti-Vinculin antibody produced in mouse, clone hVIN-1, ascites fluid
Roche
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail, Tablets provided in EASYpacks
Sigma-Aldrich
Tamoxifen, ≥99%